Arrhythmias & electrophysiology
A multicentre observational study on landiolol use, efficacy, and safety in European patients with supraventricular arrhythmia (Landi-UP)
Authors' conclusion
In European clinical practice, landiolol dosing adhered to product information recommendations. Landiolol was effective in controlling HR, with minimal impact on BP. The treatment was well tolerated, and no new safety signals were identified. These findings support the efficacy and safety of landiolol across diverse clinical settings in Europe.
Study context
- Population
- Adult patients with supraventricular arrhythmias treated with landiolol, from 17 sites across 8 European countriesenrolled, 449 were analysed
- Participants
- 450 patients
- Outcome
- Indication: atrial fibrillation
Main finding
As reported in the abstract
Most patients received landiolol for atrial fibrillation
73.1%
Observational data: associations, not effects.
Further findings
Duration of infusion and doses
- Median (IQR) duration of infusion
- 8.9 (2.3-34.0) h
- Starting dose, median (IQR)
- 5.3 (2.5-10.0) µg/kg/min
- Minimum dose, median (IQR)
- 4.0 (1.7-10) µg/kg/min
- Maximum dose, median (IQR)
- 10.0 (6.0-30.0) µg/kg/min
Heart rate (HR) control (HR ≤110 b.p.m. or a reduction of >20% from baseline) · within 4 h after treatment discontinuation
- HR control achieved
- 74.2%
Restoration of sinus rhythm
- Arrhythmia patients restoring sinus rhythm
- 36.9%
Blood pressure (BP) · throughout treatment
- BP remained stable throughout treatment
Safety
- Adverse events
- 123
- Major adverse cardiac events
- 113
- None of which were related to landiolol
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →